100 years of modelling ligand-receptor binding and response: A focus on GPCRs.

David B Finlay, Stephen B Duffull, Michelle Glass
Author Information
  1. David B Finlay: Department of Pharmacology and Toxicology, University of Otago, Dunedin, New Zealand. ORCID
  2. Stephen B Duffull: Otago Pharmacometrics Group, School of Pharmacy, University of Otago, Dunedin, New Zealand. ORCID
  3. Michelle Glass: Department of Pharmacology and Toxicology, University of Otago, Dunedin, New Zealand. ORCID

Abstract

Experimental pharmacologists rely on the application of models to describe biological observations in order to learn about a drug's effective concentration, the strength with which it binds its target and drives a response (at either molecular or system level), and the nature of more complex drug actions (allosterism/functional selectivity). Models in current use build upon decades of basic principles, going back to the beginning of the last century. Yet often, researchers are only partially familiar with these underlying principles, creating the potential for confusion due to failure to recognise the underpinning assumptions of the models that are used. Here, we describe the history of receptor theory as it underpins receptor stimulus-response models in use today, emphasising particularly attributes and models relevant to GPCRs-and point to some current aims of model development.

References

  1. J Physiol. 1957 Aug 29;138(1):63-80 [PMID: 13463799]
  2. Br J Pharmacol. 2020 Apr;177(7):1472-1484 [PMID: 31975518]
  3. Br J Pharmacol. 1985 Feb;84(2):561-71 [PMID: 3978322]
  4. J Pharmacol Exp Ther. 2007 Jan;320(1):1-13 [PMID: 16803859]
  5. Pharmacol Rev. 1955 Jun;7(2):183-265 [PMID: 13245382]
  6. Curr Protoc Pharmacol. 2008 Jun;Chapter 1:Unit1.2 [PMID: 22294216]
  7. Br J Pharmacol. 2018 May;175(10):1654-1668 [PMID: 29457969]
  8. Br J Pharmacol. 2019 Dec;176 Suppl 1:S1-S20 [PMID: 31710719]
  9. Br J Pharmacol. 2010 Nov;161(6):1276-90 [PMID: 20977467]
  10. Curr Protein Pept Sci. 2010 Feb;11(1):2-36 [PMID: 20201805]
  11. Proc R Soc Lond B Biol Sci. 1965 Aug 24;163:1-44 [PMID: 14338492]
  12. Biochem J. 1913 Oct;7(5):471-80 [PMID: 16742267]
  13. Proc Natl Acad Sci U S A. 1989 Oct;86(19):7321-5 [PMID: 2552439]
  14. Trends Pharmacol Sci. 1997 Oct;18(10):355-62 [PMID: 9357320]
  15. ACS Chem Neurosci. 2012 Mar 21;3(3):193-203 [PMID: 22860188]
  16. J Biol Chem. 1980 Aug 10;255(15):7108-17 [PMID: 6248546]
  17. J Recept Signal Transduct Res. 2006;26(4):299-327 [PMID: 16818378]
  18. Mol Pharmacol. 1998 Jul;54(1):94-104 [PMID: 9658194]
  19. J Physiol. 1909 Dec 23;39(5):361-73 [PMID: 16992989]
  20. Br J Clin Pharmacol. 2016 Jan;81(1):41-51 [PMID: 26506455]
  21. Br J Pharmacol Chemother. 1956 Dec;11(4):379-93 [PMID: 13383117]
  22. Br J Pharmacol. 2019 Jul;176(14):2593-2607 [PMID: 30945265]
  23. Trends Pharmacol Sci. 2011 Apr;32(4):189-96 [PMID: 21397341]
  24. Am J Physiol. 1948 Jun;153(3):586-600 [PMID: 18882199]
  25. Clin Exp Pharmacol Physiol. 1998 Mar-Apr;25(3-4):185-94 [PMID: 9590567]
  26. J Theor Biol. 1996 Aug 21;181(4):381-97 [PMID: 8949584]
  27. Mol Cell Endocrinol. 2019 Apr 5;485:9-19 [PMID: 30738950]
  28. Mol Pharmacol. 1984 Sep;26(2):214-27 [PMID: 6237254]
  29. Nucleic Acids Res. 2018 Jan 4;46(D1):D1091-D1106 [PMID: 29149325]
  30. Arch Int Pharmacodyn Ther. 1954 Sep 1;99(1):32-49 [PMID: 13229418]
  31. Br J Pharmacol. 2006 Jan;147 Suppl 1:S27-37 [PMID: 16402114]
  32. Br J Pharmacol. 2006 Jan;147 Suppl 1:S9-16 [PMID: 16402126]
  33. Annu Rev Pharmacol Toxicol. 2007;47:357-400 [PMID: 17067280]
  34. Trends Pharmacol Sci. 1995 Mar;16(3):89-97 [PMID: 7540781]
  35. J Pharm Pharmacol. 1966 Apr;18(4):201-22 [PMID: 4381245]
  36. J Physiol. 1926 Aug 6;61(4):547-56 [PMID: 16993814]
  37. Proc R Soc Lond B Biol Sci. 1983 Dec 22;220(1219):141-62 [PMID: 6141562]
  38. Trends Pharmacol Sci. 1993 Apr;14(4):110-2 [PMID: 8516953]
  39. ACS Chem Biol. 2008 Sep 19;3(9):530-41 [PMID: 18652471]
  40. Mol Pharmacol. 2000 Dec;58(6):1412-23 [PMID: 11093781]
  41. J Theor Biol. 2018 Jun 7;446:168-204 [PMID: 29486201]
  42. Clin Pharmacol Ther. 1979 Mar;25(3):358-71 [PMID: 761446]
  43. J Physiol. 1905 Dec 30;33(4-5):374-413 [PMID: 16992819]
  44. Annu Rev Pharmacol Toxicol. 2007;47:1-51 [PMID: 17009927]
  45. Pharmacology. 2008;82(3):171-9 [PMID: 18679046]
  46. Br J Pharmacol. 1993 Aug;109(4):1110-9 [PMID: 8401922]
  47. Biochem Pharmacol. 2014 Jan 1;87(1):93-120 [PMID: 24055064]
  48. Chem Rev. 2017 Jan 11;117(1):4-20 [PMID: 26856272]
  49. Sci Rep. 2015 Oct 01;5:14701 [PMID: 26424192]
  50. Ann N Y Acad Sci. 1954 Sep;59(2):168-81 [PMID: 13229205]
  51. Br J Pharmacol Chemother. 1947 Sep;2(3):189-206 [PMID: 20258355]
  52. Biochem Biophys Res Commun. 2012 Jan 20;417(3):982-5 [PMID: 22206668]
  53. Br J Clin Pharmacol. 2011 Jun;71(6):815-23 [PMID: 21272054]
  54. J Biol Chem. 1993 Mar 5;268(7):4625-36 [PMID: 8095262]
  55. Chem Rev. 2016 Jun 8;116(11):6707-41 [PMID: 26882314]
  56. Trends Pharmacol Sci. 1993 Aug;14(8):303-7 [PMID: 8249148]
  57. J Physiol. 1926 Aug 6;61(4):530-46 [PMID: 16993813]
  58. J Biol Chem. 1962 Mar;237:891-6 [PMID: 13897943]
  59. Nat Rev Drug Discov. 2002 Aug;1(8):637-41 [PMID: 12402503]
  60. J Pharmacol Exp Ther. 1999 Feb;288(2):478-83 [PMID: 9918548]
  61. Nature. 1956 Sep 29;178(4535):697-8 [PMID: 13369505]
  62. Biochem Pharmacol. 1973 Dec 1;22(23):3099-108 [PMID: 4202581]
  63. Br J Pharmacol. 2018 Jun;175(11):2046-2062 [PMID: 29498414]
  64. Br J Pharmacol. 2019 Dec;176 Suppl 1:S21-S141 [PMID: 31710717]
  65. Nat Commun. 2016 Feb 24;7:10842 [PMID: 26905976]
  66. Methods Mol Biol. 2009;552:51-66 [PMID: 19513641]
  67. J Theor Biol. 2018 Apr 7;442:44-65 [PMID: 29337260]
  68. J Mol Biol. 1965 May;12:88-118 [PMID: 14343300]
  69. Cell. 2017 Jul 27;170(3):414-427 [PMID: 28753422]
  70. Mol Pharmacol. 2014 Mar;85(3):492-509 [PMID: 24366668]
  71. J Physiol. 1926 Mar 18;61(1):141-50 [PMID: 16993772]
  72. Neuron. 2017 May 3;94(3):431-446 [PMID: 28472649]
  73. Pharmacol Rev. 1953 Mar;5(1):87-134 [PMID: 13046989]
  74. J Physiol. 1901 Oct 16;27(3):224-36 [PMID: 16992584]
  75. Br J Pharmacol. 2008 Mar;153(5):841-3 [PMID: 18204481]
  76. Proc R Soc Lond B Biol Sci. 1957 May 7;146(924):369-81 [PMID: 13431862]
  77. Trends Pharmacol Sci. 2004 Apr;25(4):186-92 [PMID: 15063082]
  78. Trends Pharmacol Sci. 2007 Dec;28(12):608-14 [PMID: 18023486]

Grants

  1. /Lottery Health Research Postdoctoral Fellowship

MeSH Term

Ligands
Protein Binding
Receptors, G-Protein-Coupled

Chemicals

Ligands
Receptors, G-Protein-Coupled

Word Cloud

Created with Highcharts 10.0.0modelsdescribecurrentuseprinciplesreceptorExperimentalpharmacologistsrelyapplicationbiologicalobservationsorderlearndrug'seffectiveconcentrationstrengthbindstargetdrivesresponseeithermolecularsystemlevelnaturecomplexdrugactionsallosterism/functionalselectivityModelsbuildupondecadesbasicgoingbackbeginninglastcenturyYetoftenresearcherspartiallyfamiliarunderlyingcreatingpotentialconfusionduefailurerecogniseunderpinningassumptionsusedhistorytheoryunderpinsstimulus-responsetodayemphasisingparticularlyattributesrelevantGPCRs-andpointaimsmodeldevelopment100yearsmodellingligand-receptorbindingresponse:focusGPCRs

Similar Articles

Cited By